drugset
drugset / Trial / NCT06066424

Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)

NCT06066424 ↗

Phase 1 Recruiting 54 enrolled M.D. Anderson Cancer Center Bellicum Pharmaceuticals · collab
RandomizedSingle-groupOpen-labelTreatment

Summary

To find the recommended dose of TROP2- CAR-NK cells that can be given to participants with advanced forms of solid tumors.

Timeline

Start
2023-10-24
Primary completion
2038-04-30
Completion
2040-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject TROP2-CAR-NK Cells Cell therapy — Intravenous
Background Cyclophosphamide Other / unclassified — Intravenous
Background Fludarabine Small molecule — Intravenous
Background Rimiducid Other / unclassified — Intravenous

Indications

cancer